Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSP008-22 in Advanced Solid Tumours
NCT05478486Phase 1Completed
- Sponsor
- Godavari Biorefineries
- Start
- Feb 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MSP008-22 in solid tumor (advanced stage), sponsored by Godavari Biorefineries. Primary endpoints: Maximum Tolerated Dose at 10 days, Dose-Limiting Toxicities at 10 days and 1 more. Started Feb 2023; status: completed.
02
Drugs
MSP008-22
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05478486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478486.